Development and Validation of a Nomogram for Predicting Overall Survival to Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

Table 1

Characteristics of patients.

Variable	Total ()	Training set ()	Validation set ()	value
Age (years, )				0.594
Tumor length (cm, )				0.357
Radiotherapy dose (Gy, )				0.790
NLR ()				0.468
PLR ()				0.059
MLR (per 0.1 change) ()				0.819
Sex ()				0.674
Female	174 (34.6)	118 (35.2)	56 (33.3)
Male	329 (65.4)	217 (64.8)	112 (66.7)
Location ()				0.429
Neck/upper	287 (57.1)	187 (55.8)	100 (59.5)
Middle/lower	216 (42.9)	148 (44.2)	68 (40.5)
T stage ()				0.278
T1-T2	135 (26.8)	90 (26.9)	45 (26.8)
T3	119 (23.7)	86 (25.7)	33 (19.6)
T4	249 (49.5)	159 (47.5)	90 (53.6)
N stage ()				0.963
N0	161 (32.0)	107 (31.9)	54 (32.1)
N+	342 (68.0)	228 (68.1)	114 (67.9)
Clinical stage ()				0.369
II	123 (24.5)	86 (25.7)	37 (22.0)
III	380 (75.5)	249 (74.3)	131 (78.0)
Radiotherapy type ()				0.971
IMRT	285 (56.7)	190 (56.7)	95 (56.5)
3DCRT	218 (43.3)	145 (43.3)	73 (43.5)
Adjuvant chemotherapy ()				0.469
No	267 (53.1)	174 (51.9)	93 (55.4)
Yes	236 (46.9)	161 (48.1)	75 (44.6)
Tumor response ()				0.517
CR	113 (22.5)	78 (23.3)	35 (20.8)
PR	351 (69.8)	234 (69.9)	117 (69.6)
SD/PD	39 (7.8)	23 (6.9)	16 (9.5)

NLR: neutrophil/lymphocyte ratio; PLR: platelet/lymphocyte ratio; MLR: monocyte/lymphocyte ratio; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; IMRT: intensity-modulated radiotherapy; 3DCRT: three-dimensional conformal radiotherapy.